Atossa Signs on Third PPO for Breast Cancer Test | GenomeWeb

NEW YORK (GenomeWeb News) – Atossa Genetics today said into has signed a nationwide agreement with preferred provider organization HealthSmart.

The agreement, the Seattle-based breast cancer diagnostic firm said, is to provide patients in HealthSmart's network greater access to Atossa's ForeCyte Breast Health Test. The risk stratification test for breast cancer is based on Atossa's US Food and Drug Administration-cleared Mammary Aspirate Specimen Cytology Test System, or MASCT.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.